Acute Effect of Imeglimin Add-on Therapy on 24-h Glucose Profile and Glycemic Variability in Patients with Type 2 Diabetes Receiving Metformin
Abstract Introduction: Imeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We investigated acute effects of add-on therapy with imeglimin to preceding metformin on the 24-h glucose profile and glycemic variability asses...
Saved in:
| Published in | Medical principles and practice Vol. 33; no. 6; pp. 569 - 577 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Basel, Switzerland
S. Karger AG
01.12.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1011-7571 1423-0151 1423-0151 |
| DOI | 10.1159/000540852 |
Cover
Loading…
| Abstract | Abstract
Introduction: Imeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We investigated acute effects of add-on therapy with imeglimin to preceding metformin on the 24-h glucose profile and glycemic variability assessed by continuous glucose monitoring (CGM) in patients with type 2 diabetes. Methods: We studied 30 outpatients with type 2 diabetes inadequately controlled with metformin. CGM was used for 14 days straight during the research period. Imeglimin 2,000 mg/day was started on day 7 after initiating CGM. Several CGM parameters were compared between days 4–6 (prior to imeglimin treatment) and 11–13 (following the initiation of imeglimin treatment). Results: After treatment with imeglimin, 24-h mean glucose was acutely decreased from 161.6 ± 48.0 mg/dL to 138.9 ± 32.2 mg/dL (p < 0.0001), while time in range (i.e., at a glucose level of 70–180 mg/dL) was significantly increased from 69.9 ± 23.9% to 80.6 ± 21.0% (p < 0.0001). Addition of imeglimin to metformin significantly decreased the standard deviation (SD) of 24-h glucose and mean amplitude of glycemic excursions, 2 indexes of glycemic variability. Baseline serum high-density lipoprotein (HDL) cholesterol was negatively correlated with changes in mean 24-h glucose (r = −0.3859, p = 0.0352) and those in SD (r = −0.4015, p = 0.0309). Conclusions: Imeglimin add-on therapy to metformin acutely lowered 24-h glucose levels and improved glycemic variability in patients with type 2 diabetes on metformin. A higher serum HDL cholesterol at baseline was associated with a better response to acute effects of imeglimin on 24-h glucose levels and glycemic variability. |
|---|---|
| AbstractList | Introduction: Imeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We investigated acute effects of add-on therapy with imeglimin to preceding metformin on the 24-h glucose profile and glycemic variability assessed by continuous glucose monitoring (CGM) in patients with type 2 diabetes. Methods: We studied 30 outpatients with type 2 diabetes inadequately controlled with metformin. CGM was used for 14 days straight during the research period. Imeglimin 2,000 mg/day was started on day 7 after initiating CGM. Several CGM parameters were compared between days 4–6 (prior to imeglimin treatment) and 11–13 (following the initiation of imeglimin treatment). Results: After treatment with imeglimin, 24-h mean glucose was acutely decreased from 161.6 ± 48.0 mg/dL to 138.9 ± 32.2 mg/dL (p < 0.0001), while time in range (i.e., at a glucose level of 70–180 mg/dL) was significantly increased from 69.9 ± 23.9% to 80.6 ± 21.0% (p < 0.0001). Addition of imeglimin to metformin significantly decreased the standard deviation (SD) of 24-h glucose and mean amplitude of glycemic excursions, 2 indexes of glycemic variability. Baseline serum high-density lipoprotein (HDL) cholesterol was negatively correlated with changes in mean 24-h glucose (r = −0.3859, p = 0.0352) and those in SD (r = −0.4015, p = 0.0309). Conclusions: Imeglimin add-on therapy to metformin acutely lowered 24-h glucose levels and improved glycemic variability in patients with type 2 diabetes on metformin. A higher serum HDL cholesterol at baseline was associated with a better response to acute effects of imeglimin on 24-h glucose levels and glycemic variability. Continuous glucose monitoring (CGM) can provide information on 24-h mean blood glucose level, time in the glucose target range (TIR), and indices of glycemic variability. [...]the present study used (CGM) to investigate the acute effect of imeglimin add-on therapy on 24-h glucose levels and glycemic variability in patients with type 2 diabetes receiving metformin. Demographic, clinical, and laboratory data for patients with type 2 diabetes receiving metformin at baseline Variables N (M/F) 30 (23/7) Age, years 60.5±13.6 Body weight, kg 69.7±12.6 BMI, kg/m2 25.0±3.5 Diabetes duration, years 7.5 (2, 13.5) FPG, mg/dL 170.3±84.4 HbA1c, % 8.1±1.3 Fasting C peptide, ng/dL 2.93 (2.03, 3.65) LDL-C, mg/dL 96.5±27.9 HDL-C, mg/dL 58.3±24.1 Triglyceride, mg/dL 127 (94.5, 144) eGFR, mL/min/1.73 m2 78.5±19.4 CGM data 24-h mean glucose, mg/dL 161.6±48.0 Mean postprandial glucose Breakfast, mg/dL 145.6±51.4 Lunch, mg/dL 158.0±70.2 Dinner, mg/dL 161.1±73.6 GMI, % 7.2±1.2 SD of 24-h glucose, mg/dL 41.6±13.6 CV, % 25.8±5.8 MAGE, mg/dL 103.3±34.7 TIR, % 69.9±23.4 TBR, % 0 (0, 0) TAR, % 24.0 (10.5, 40.0) Antidiabetic drugs Metformin use, n (%) 30 (100) Mean dose, mg 992 SU use, n (%) 10 (33.3) α-GI use, n (%) 1 (3.33) Insulin use, n (%) 13 (43.3) DPP-4 inhibitors, n (%) 15 (20.0) GLP-1RA, n (%) 16 (53.3) SGLT2 inhibitors, n (%) 21 (70.0) Pioglitazone, n (%) 1 (3.33) Data are the mean ± SD, number (percentage) or the median and interquartile ranges. BMI, body mass index; FPG, fasting plasma glucose; Hb, hemoglobin; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration; CGM, continuous glucose monitoring; GMI, glucose monitoring index; SD, standard deviation; CV, coefficient of variation; MAGE, mean amplitude of glycemic excursions; TIR, time in range; TBR, time below range; TAR, time above range; SU, sulfonylurea; α-GI, alfa-glucosidase inhibitors; DPP, dipeptidyl peptidase; GLP-1RA, glucagon-like peptide-1 receptor agonists; SGLT2, sodium-glucose co-transporter 2. GMI, glucose monitoring index; SD, standard deviation; CV, coefficient of variation; MAGE, mean amplitude of glycemic excursions; MPPGE, mean of postprandial glucose excursion; TIR, time in range; TBR, time below range; TAR, time above range. Abstract Introduction: Imeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We investigated acute effects of add-on therapy with imeglimin to preceding metformin on the 24-h glucose profile and glycemic variability assessed by continuous glucose monitoring (CGM) in patients with type 2 diabetes. Methods: We studied 30 outpatients with type 2 diabetes inadequately controlled with metformin. CGM was used for 14 days straight during the research period. Imeglimin 2,000 mg/day was started on day 7 after initiating CGM. Several CGM parameters were compared between days 4–6 (prior to imeglimin treatment) and 11–13 (following the initiation of imeglimin treatment). Results: After treatment with imeglimin, 24-h mean glucose was acutely decreased from 161.6 ± 48.0 mg/dL to 138.9 ± 32.2 mg/dL (p < 0.0001), while time in range (i.e., at a glucose level of 70–180 mg/dL) was significantly increased from 69.9 ± 23.9% to 80.6 ± 21.0% (p < 0.0001). Addition of imeglimin to metformin significantly decreased the standard deviation (SD) of 24-h glucose and mean amplitude of glycemic excursions, 2 indexes of glycemic variability. Baseline serum high-density lipoprotein (HDL) cholesterol was negatively correlated with changes in mean 24-h glucose (r = −0.3859, p = 0.0352) and those in SD (r = −0.4015, p = 0.0309). Conclusions: Imeglimin add-on therapy to metformin acutely lowered 24-h glucose levels and improved glycemic variability in patients with type 2 diabetes on metformin. A higher serum HDL cholesterol at baseline was associated with a better response to acute effects of imeglimin on 24-h glucose levels and glycemic variability. Imeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We investigated acute effects of add-on therapy with imeglimin to preceding metformin on the 24-h glucose profile and glycemic variability assessed by continuous glucose monitoring (CGM) in patients with type 2 diabetes.INTRODUCTIONImeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We investigated acute effects of add-on therapy with imeglimin to preceding metformin on the 24-h glucose profile and glycemic variability assessed by continuous glucose monitoring (CGM) in patients with type 2 diabetes.We studied 30 outpatients with type 2 diabetes inadequately controlled with metformin. CGM was used for 14 days straight during the research period. Imeglimin 2,000 mg/day was started on day 7 after initiating CGM. Several CGM parameters were compared between days 4-6 (prior to imeglimin treatment) and 11-13 (following the initiation of imeglimin treatment).METHODSWe studied 30 outpatients with type 2 diabetes inadequately controlled with metformin. CGM was used for 14 days straight during the research period. Imeglimin 2,000 mg/day was started on day 7 after initiating CGM. Several CGM parameters were compared between days 4-6 (prior to imeglimin treatment) and 11-13 (following the initiation of imeglimin treatment).After treatment with imeglimin, 24-h mean glucose was acutely decreased from 161.6 ± 48.0 mg/dL to 138.9 ± 32.2 mg/dL (p < 0.0001), while time in range (i.e., at a glucose level of 70-180 mg/dL) was significantly increased from 69.9 ± 23.9% to 80.6 ± 21.0% (p < 0.0001). Addition of imeglimin to metformin significantly decreased the standard deviation (SD) of 24-h glucose and mean amplitude of glycemic excursions, 2 indexes of glycemic variability. Baseline serum high-density lipoprotein (HDL) cholesterol was negatively correlated with changes in mean 24-h glucose (r = -0.3859, p = 0.0352) and those in SD (r = -0.4015, p = 0.0309).RESULTSAfter treatment with imeglimin, 24-h mean glucose was acutely decreased from 161.6 ± 48.0 mg/dL to 138.9 ± 32.2 mg/dL (p < 0.0001), while time in range (i.e., at a glucose level of 70-180 mg/dL) was significantly increased from 69.9 ± 23.9% to 80.6 ± 21.0% (p < 0.0001). Addition of imeglimin to metformin significantly decreased the standard deviation (SD) of 24-h glucose and mean amplitude of glycemic excursions, 2 indexes of glycemic variability. Baseline serum high-density lipoprotein (HDL) cholesterol was negatively correlated with changes in mean 24-h glucose (r = -0.3859, p = 0.0352) and those in SD (r = -0.4015, p = 0.0309).Imeglimin add-on therapy to metformin acutely lowered 24-h glucose levels and improved glycemic variability in patients with type 2 diabetes on metformin. A higher serum HDL cholesterol at baseline was associated with a better response to acute effects of imeglimin on 24-h glucose levels and glycemic variability.CONCLUSIONSImeglimin add-on therapy to metformin acutely lowered 24-h glucose levels and improved glycemic variability in patients with type 2 diabetes on metformin. A higher serum HDL cholesterol at baseline was associated with a better response to acute effects of imeglimin on 24-h glucose levels and glycemic variability. Imeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We investigated acute effects of add-on therapy with imeglimin to preceding metformin on the 24-h glucose profile and glycemic variability assessed by continuous glucose monitoring (CGM) in patients with type 2 diabetes. We studied 30 outpatients with type 2 diabetes inadequately controlled with metformin. CGM was used for 14 days straight during the research period. Imeglimin 2,000 mg/day was started on day 7 after initiating CGM. Several CGM parameters were compared between days 4-6 (prior to imeglimin treatment) and 11-13 (following the initiation of imeglimin treatment). After treatment with imeglimin, 24-h mean glucose was acutely decreased from 161.6 ± 48.0 mg/dL to 138.9 ± 32.2 mg/dL (p < 0.0001), while time in range (i.e., at a glucose level of 70-180 mg/dL) was significantly increased from 69.9 ± 23.9% to 80.6 ± 21.0% (p < 0.0001). Addition of imeglimin to metformin significantly decreased the standard deviation (SD) of 24-h glucose and mean amplitude of glycemic excursions, 2 indexes of glycemic variability. Baseline serum high-density lipoprotein (HDL) cholesterol was negatively correlated with changes in mean 24-h glucose (r = -0.3859, p = 0.0352) and those in SD (r = -0.4015, p = 0.0309). Imeglimin add-on therapy to metformin acutely lowered 24-h glucose levels and improved glycemic variability in patients with type 2 diabetes on metformin. A higher serum HDL cholesterol at baseline was associated with a better response to acute effects of imeglimin on 24-h glucose levels and glycemic variability. |
| Author | Sakurai, Shintaro Tomaru, Takuya Inoue, Teruo Aso, Yoshimasa Kamiga, Yusuke Akutsu, Ikuo Shinohara, Yasutake Jojima, Teruo Iijima, Toshie Usui, Isao |
| Author_xml | – sequence: 1 givenname: Yasutake surname: Shinohara fullname: Shinohara, Yasutake – sequence: 2 givenname: Teruo surname: Jojima fullname: Jojima, Teruo – sequence: 3 givenname: Yusuke surname: Kamiga fullname: Kamiga, Yusuke – sequence: 4 givenname: Shintaro surname: Sakurai fullname: Sakurai, Shintaro – sequence: 5 givenname: Toshie surname: Iijima fullname: Iijima, Toshie – sequence: 6 givenname: Takuya surname: Tomaru fullname: Tomaru, Takuya – sequence: 7 givenname: Ikuo surname: Akutsu fullname: Akutsu, Ikuo – sequence: 8 givenname: Teruo surname: Inoue fullname: Inoue, Teruo – sequence: 9 givenname: Isao surname: Usui fullname: Usui, Isao – sequence: 10 givenname: Yoshimasa surname: Aso fullname: Aso, Yoshimasa email: *Yoshimasa Aso, yaso@dokkyomed.ac.jp |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39134001$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkk9v1DAQxS1URP_AgTtClnqBQ8CO7WxyQqtSSqVWrNDC1XLsya5LYgfbaZUv0c-MYcsKEL545PfTmzfyHKMD5x0g9JySN5SK5i0hRHBSi_IROqK8ZAWhgh7kmlBaLMSCHqLjGG8yVjNGnqBD1lDGCaFH6H6ppwT4vOtAJ-w7fDnApreDdXhpTOEdXm8hqHHGuSx5scUX_aR9BLwKvrM9YOVMfps1DFbjrypY1drephlni5VKFlyK-M6mLV7PI-ASv88EJIj4M2iwt9Zt8DWkzofc9Cl63Kk-wrOH-wR9-XC-PvtYXH26uDxbXhWa1yQVCnTbNIaXNdFK5KN1J0TbUq0qkWeriamNYZwZQytNWlOD0I1SojGaG8PZCXq38x2ndgCjc8igejkGO6gwS6-s_Ftxdis3_lZSWjFKOM0Orx4cgv8-QUxysFFD3ysHfoqSkaZkVVX9Qk__QW_8FFyeTzLKWVlVrFpk6uWfkfZZfv9VBl7vAB18jAG6PUKJ_LkHcr8HmX2xY7-psIGwJ_fy6X_l69VqR8jRdOwHBT25-w |
| Cites_doi | 10.2337/db14-1220 10.1111/dom.14277 10.1016/j.dsx.2023.102710 10.2337/db05-1525 10.1111/dom.12452 10.2337/dc12-0453 10.1111/j.1463-1326.2012.01611.x 10.3390/ijms23158320 10.14814/phy2.15151 10.1016/j.dsx.2021.102323 10.1007/s40268-015-0099-3 10.1007/s13300-022-01298-w 10.1111/dom.14613 10.1007/s00125-015-3525-8 10.1152/ajpendo.00009.2016 10.1002/edm2.211 10.1111/jdi.14001 10.2337/dc23-s009 10.2337/dc18-1581 10.2337/dc20-0763 10.1371/journal.pone.0241651 10.1038/nature13270 10.1038/s41598-023-27689-y 10.1111/dom.14642 |
| ContentType | Journal Article |
| Copyright | 2024 The Author(s). Published by S. Karger AG, Basel 2024 The Author(s). Published by S. Karger AG, Basel. 2024 The Author(s). Published by S. Karger AG, Basel. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content 2024 The Author(s). Published by S. Karger AG, Basel 2024 |
| Copyright_xml | – notice: 2024 The Author(s). Published by S. Karger AG, Basel – notice: 2024 The Author(s). Published by S. Karger AG, Basel. – notice: 2024 The Author(s). Published by S. Karger AG, Basel. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content – notice: 2024 The Author(s). Published by S. Karger AG, Basel 2024 |
| DBID | M-- AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1159/000540852 |
| DatabaseName | Karger Open Access Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef ProQuest One Academic Middle East (New) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: M-- name: Karger Open Access Journals url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Acute Effects of Imeglimin Evaluated by CGM |
| EISSN | 1423-0151 |
| EndPage | 577 |
| ExternalDocumentID | PMC11631041 39134001 10_1159_000540852 540852 |
| Genre | Journal Article |
| GroupedDBID | --- 0R~ 0~B 326 36B 3O. 4.4 53G 5GY 7X7 88E 8FI 8FJ 8UI AAWTL AAYIC ABBTS ABPAZ ABUWG ABWCG ACGFS ADBBV AENEX AEYAO AFKRA AHFRZ AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZPMC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CS3 DU5 E0A E3Z EBS EMB EMOBN F5P FB. FYUFA GROUPED_DOAJ HMCUK HYE HZ~ IAO IHR ITC KUZGX M-- M1P MK0 O1H O9- OK1 P2P PHGZT PQQKQ PROAC PSQYO RKO RNS RPM SV3 UJ6 UKHRP AAYXX CITATION CYUIP PHGZM 30W 3V. ACQXL ADAGL AFJJK AFSIO AIOBO CAG CGR COF CUY CVF DIK ECM EIF EJD NPM RIG RXVBD TR2 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c480t-aecb99d4280ca5555ccf55bb1ca6591380d8dd343dd16c0bd8e5c9aa59dc4dd43 |
| IEDL.DBID | BENPR |
| ISSN | 1011-7571 1423-0151 |
| IngestDate | Thu Aug 21 18:29:42 EDT 2025 Fri Sep 05 13:01:50 EDT 2025 Fri Jul 25 20:42:38 EDT 2025 Wed Feb 19 02:17:53 EST 2025 Sun Jul 06 05:06:51 EDT 2025 Fri Apr 25 05:07:35 EDT 2025 Fri Apr 25 05:07:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Imeglimin Continuous glucose monitoring Metformin Glycemic variability Acute effect Time in range |
| Language | English |
| License | This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. https://creativecommons.org/licenses/by-nc/4.0 2024 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c480t-aecb99d4280ca5555ccf55bb1ca6591380d8dd343dd16c0bd8e5c9aa59dc4dd43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://karger.com/doi/10.1159/000540852 |
| PMID | 39134001 |
| PQID | 3143266367 |
| PQPubID | 2047984 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_3092366641 pubmed_primary_39134001 crossref_primary_10_1159_000540852 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11631041 proquest_journals_3143266367 karger_primary_540852 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-12-01 |
| PublicationDateYYYYMMDD | 2024-12-01 |
| PublicationDate_xml | – month: 12 year: 2024 text: 2024-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Basel |
| PublicationTitle | Medical principles and practice |
| PublicationTitleAlternate | Med Princ Pract |
| PublicationYear | 2024 |
| Publisher | S. Karger AG |
| Publisher_xml | – name: S. Karger AG |
| References | Oda T, Satoh M, Nagasawa K, Sasaki A, Hasegawa Y, Takebe N, . The effects of imeglimin on the daily glycemic profile evaluated by intermittently scanned continuous glucose monitoring: retrospective, single-center, observational study. Diabetes Ther. 2022;13(9):1635–43. Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, . Mechanism of action of Imeglimin: a novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021;23(3):664–73. Vial G, Lamarche F, Cottet-Rousselle C, Hallakou-Bozec S, Borel AL, Fontaine E. The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells. Ndocrinol Diabetes Metab. 2021;4(2):e00211. Singh AK, Singh A, Singh R, Misra A. Efficacy and safety of imeglimin in type 2 diabetes: a systematic review and meta-analysis of randomized placebo-controlled trials. Diabetes Metab Syndr. 2023;17:102710. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, . Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes. 2006;55(7):1954–60. Theurey P, Vial G, Fontaine E, Monternier PA, Fouqueray P, Bolze S, . Reduced lactic acidosis risk with imeglimin: comparison with metformin. Physiol Rep. 2022;10(5):e15151. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65. Yingyue Q, Sugawara K, Takahashi H, Yokoi N, Ohbayashi K, Iwasaki Y, . Stimulatory effect of imeglimin on incretin secretion. J Diabetes Investig. 2023;14(6):746–55. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we. Diabetologia. 2015;58(5):886–99. Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, . Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015;64(6):2254–64. Dubourg J, Fouqueray P, Quinslot D, Grouin JM, Kaku K. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week, open-label, multicentre phase 3 trial. Diabetes Obes Metab. 2022;24(4):609–19. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, . Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–6. Di Mauro S, Filippello A, Scamporrino A, Purrello F, Piro S, Malaguarnera R. Metformin: when should we fear lactic acidosis. Int J Mol Sci. 2022;23(15):8320. Reilhac C, Dubourg J, Thang C, Grouin JM, Fouqueray P, Watada H. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): a randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes Obes Metab. 2022;24(5):838–48. Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K. Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes (times 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial. Diabetes Care. 2021;44(4):952–9. Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, . Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275–80. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, . 9. Pharmacologic approaches to glycemic treatment: standards of Care in diabetes—2023. Diabetes Care. 2022;46(Suppl ment_1):S140–57. Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou-Bozec S, . Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab. 2016;311(2):E461–70. Hallakou-Bozec S, Kergoat M, Fouqueray P, Bolze S, Moller DE. Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS One. 2021;16(2):e0241651. Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs R D. 2015;15(3):227–32. Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G, Diamant M, . The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013;36(3):565–8. Pacini G, Mari A, Fouqueray P, Bolze S, Roden M. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(6):541–5. Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012;14(9):852–8. Hozumi K, Sugawara K, Ishihara T, Ishihara N, Ogawa W. Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes. Sci Rep. 2023;13(1):746. Abdelhaleem IA, Salamah HM, Alsabbagh FA, Eid AM, Hussien HM, Mohamed NI, . Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Diabetes Metab Syndr. 2021;15(6):102323. ref13 ref24 ref12 ref23 ref15 ref14 ref20 ref11 ref22 ref10 ref21 ref2 ref1 ref17 ref16 ref19 ref18 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – reference: Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, . Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–6. – reference: Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou-Bozec S, . Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab. 2016;311(2):E461–70. – reference: Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, . Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275–80. – reference: Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, . Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes. 2006;55(7):1954–60. – reference: Reilhac C, Dubourg J, Thang C, Grouin JM, Fouqueray P, Watada H. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): a randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes Obes Metab. 2022;24(5):838–48. – reference: Hallakou-Bozec S, Kergoat M, Fouqueray P, Bolze S, Moller DE. Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS One. 2021;16(2):e0241651. – reference: Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs R D. 2015;15(3):227–32. – reference: Hozumi K, Sugawara K, Ishihara T, Ishihara N, Ogawa W. Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes. Sci Rep. 2023;13(1):746. – reference: Pacini G, Mari A, Fouqueray P, Bolze S, Roden M. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(6):541–5. – reference: Dubourg J, Fouqueray P, Quinslot D, Grouin JM, Kaku K. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week, open-label, multicentre phase 3 trial. Diabetes Obes Metab. 2022;24(4):609–19. – reference: Abdelhaleem IA, Salamah HM, Alsabbagh FA, Eid AM, Hussien HM, Mohamed NI, . Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Diabetes Metab Syndr. 2021;15(6):102323. – reference: Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we. Diabetologia. 2015;58(5):886–99. – reference: Vial G, Lamarche F, Cottet-Rousselle C, Hallakou-Bozec S, Borel AL, Fontaine E. The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells. Ndocrinol Diabetes Metab. 2021;4(2):e00211. – reference: Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, . Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015;64(6):2254–64. – reference: Singh AK, Singh A, Singh R, Misra A. Efficacy and safety of imeglimin in type 2 diabetes: a systematic review and meta-analysis of randomized placebo-controlled trials. Diabetes Metab Syndr. 2023;17:102710. – reference: ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, . 9. Pharmacologic approaches to glycemic treatment: standards of Care in diabetes—2023. Diabetes Care. 2022;46(Suppl ment_1):S140–57. – reference: Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, . Mechanism of action of Imeglimin: a novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021;23(3):664–73. – reference: Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G, Diamant M, . The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013;36(3):565–8. – reference: UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65. – reference: Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K. Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes (times 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 3 trial. Diabetes Care. 2021;44(4):952–9. – reference: Oda T, Satoh M, Nagasawa K, Sasaki A, Hasegawa Y, Takebe N, . The effects of imeglimin on the daily glycemic profile evaluated by intermittently scanned continuous glucose monitoring: retrospective, single-center, observational study. Diabetes Ther. 2022;13(9):1635–43. – reference: Yingyue Q, Sugawara K, Takahashi H, Yokoi N, Ohbayashi K, Iwasaki Y, . Stimulatory effect of imeglimin on incretin secretion. J Diabetes Investig. 2023;14(6):746–55. – reference: Di Mauro S, Filippello A, Scamporrino A, Purrello F, Piro S, Malaguarnera R. Metformin: when should we fear lactic acidosis. Int J Mol Sci. 2022;23(15):8320. – reference: Theurey P, Vial G, Fontaine E, Monternier PA, Fouqueray P, Bolze S, . Reduced lactic acidosis risk with imeglimin: comparison with metformin. Physiol Rep. 2022;10(5):e15151. – reference: Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012;14(9):852–8. – ident: ref6 doi: 10.2337/db14-1220 – ident: ref3 doi: 10.1111/dom.14277 – ident: ref7 doi: 10.1016/j.dsx.2023.102710 – ident: ref21 doi: 10.2337/db05-1525 – ident: ref5 doi: 10.1111/dom.12452 – ident: ref9 doi: 10.2337/dc12-0453 – ident: ref15 doi: 10.1111/j.1463-1326.2012.01611.x – ident: ref2 doi: 10.3390/ijms23158320 – ident: ref8 doi: 10.14814/phy2.15151 – ident: ref19 doi: 10.1016/j.dsx.2021.102323 – ident: ref4 doi: 10.1007/s40268-015-0099-3 – ident: ref12 doi: 10.1007/s13300-022-01298-w – ident: ref10 doi: 10.1111/dom.14613 – ident: ref20 doi: 10.1007/s00125-015-3525-8 – ident: ref24 doi: 10.1152/ajpendo.00009.2016 – ident: ref22 doi: 10.1002/edm2.211 – ident: ref16 doi: 10.1111/jdi.14001 – ident: ref1 doi: 10.2337/dc23-s009 – ident: ref11 doi: 10.2337/dc18-1581 – ident: ref13 doi: 10.2337/dc20-0763 – ident: ref17 doi: 10.1371/journal.pone.0241651 – ident: ref18 doi: 10.1038/nature13270 – ident: ref23 doi: 10.1038/s41598-023-27689-y – ident: ref14 doi: 10.1111/dom.14642 |
| SSID | ssj0008330 |
| Score | 2.3534412 |
| Snippet | Abstract
Introduction: Imeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We... Introduction: Imeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We... Imeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We investigated acute... Continuous glucose monitoring (CGM) can provide information on 24-h mean blood glucose level, time in the glucose target range (TIR), and indices of glycemic... |
| SourceID | pubmedcentral proquest pubmed crossref karger |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 569 |
| SubjectTerms | Acidosis Adult Aged Antidiabetics Blood Glucose - analysis Blood Glucose - drug effects Body mass index Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Drug dosages Drug Therapy, Combination Female Glucose monitoring Glycated Hemoglobin - analysis Glycated Hemoglobin - drug effects Hemoglobin High density lipoprotein Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Insulin Lipoproteins Male Metformin - therapeutic use Middle Aged Original Paper Peptides Triazines - administration & dosage Triazines - therapeutic use |
| SummonAdditionalLinks | – databaseName: Karger Open Access Journals dbid: M-- link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1NT9wwEB1VUCEuCFoo4UsD6tVqHNvZ5LhCUIqUag9QcYsc2ymrlixiswf-BL-Z8TqJuojmFNlOrMzYnjf25A3A1yrNtbf7zFlZk4NCM73KjWZa10aQRZJce0ex-Jle3crrO3XX7Xf4f2H--PjnJTXqwC1ABvdbgBaZosV2nfwo4XMVFIwNa24mROAd4JyN1Ih3HEIrj27ChvDnzHGXAKY3Qh9Dn-9BzLeRkv-Ynstt2OowI46Dknfgg2s-wUbRnYp_hpexWbQOAxExzmr88eB-__XpunBsLZs1eBO4A5BuE8nu8XsIVMdJyNiNurFU9mx8pDz-Ivc5sHc_I71iEphX5-i3bNH7rZhgF0gzR4Kdbuo3JbBwrQfA02YXbi8vbs6vWJdngRmZxS3TzlR5bskRiY1WdBlTK1VV3OhUkcSy2GbWCims5amJK5s5ZXKtVW6NtFaKPVhrZo3bB0xMSi144qNHpRjV2ps7o6s0JrknKovgrBd8-RjoNMqlG6LyclBUBLtBJUOTvvzoTXkxmYSq8tHWVN0rsOwm4rwUhAcJg4h0FMHpUE1TyJ-L6MbNFtQmJpRLbpzkEXwJ-h566EdMBNnKSBgaeHru1Zpmer-k6eYEdUkK_OA_n3MImwkhpBAbcwRr7dPCHRPCaauT5eB-BXec9B8 priority: 102 providerName: Karger AG |
| Title | Acute Effect of Imeglimin Add-on Therapy on 24-h Glucose Profile and Glycemic Variability in Patients with Type 2 Diabetes Receiving Metformin |
| URI | https://karger.com/doi/10.1159/000540852 https://www.ncbi.nlm.nih.gov/pubmed/39134001 https://www.proquest.com/docview/3143266367 https://www.proquest.com/docview/3092366641 https://pubmed.ncbi.nlm.nih.gov/PMC11631041 |
| Volume | 33 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1db9MwFL1iHUK8ID4GBEZlEK_W4tjOxxMqaGMgZYrQhvoWObazVUBS1vRhf4LfzHXtBjoh8lBFttVWvrbPvddH5wK8bdJCOdyn1ogWAxTc6U2hFVWq1RwRSTDlAsXyLD29EJ_nch4SbqtAq9yeiZuD2vTa5ciPOAI7gglPs3fLn9RVjXK3q6GExh7s4xGcywnsvz8-q76MZ3HOudcjYIxmMmNBWwgx_Mh7K7lMdhDp7jdHwL7-l795mzb5Fw6dPIQHwYEkM2_xR3DHdo_hXhmuyJ_Ar5leD5Z4VWLSt-TTD3v53dXuIjNjaN-Rcy8kQPA1EfSKfPSsdVL58t1EdQbbbrSjzZOvGEt7Ke8bgl9ReRnWFXH5W-KCWJKQwKpZEfRB7cJlKEhpB-cNL7oDuDg5Pv9wSkPRBapFHg9UWd0UhcGoJNZK4qN1K2XTMK1SWTCexyY3hgtuDEt13JjcSl0oJQujhTGCP4VJ13f2OZBEpziCJY5KKnjWKod9WjVpzDFqlXkEb7YTXy-9tka9iUlkUY_WieDAm2Qcsm0_vNVeVpXvqpemxe6tAeuwK1f1nzUUweuxG_eTuyRRne3XOCZGlxdjOsEieObtPf4CdzQFxPUI8p2VMA5wWt27Pd3iaqPZzdDvxVlgL_7_v17C_QS9Js-XOYTJcL22r9DrGZop7GXzbBoW-HSTO8DPktLf8hUDvw |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFL0aG2K8ID4GBAYYBI_R4thOkweECmy0bK0i1KG9ZY7tbBWQlDUV6p_gp_Abua6TQCfE2_oU2VYa5V77nmufnAvwMo8SaeO-bzQvMEHBmZ4nSvpSFophROJU2kRxNI4Gx_zjiTjZgF_ttzCWVtmuiauFWlfK7pHvMQzsGExY1Hsz--7bqlH2dLUtoeHc4tAsf2DKNn89fI_2fRWGB_uTdwO_qSrgKx4HtS-NypNEI-wOlBT4U6oQIs-pkpFIKIsDHWvNONOaRirIdWyESqQUiVZca87wvtdgC2FGgrNo6-3-OP3Urf0xY07_gFK_J3q00TJCzLDn0FEswrUIeP2LJXxf_AvfXqZp_hX3Dm7DrQawkr7zsDuwYcq7cGPUHMnfg599tagNcSrIpCrI8Js5-2prhZG-1n5VkokTLiB4GXL_nHxwLHmSunLhRJYa25bK0vTJZ8zdnXT4kuAtUif7Oid2v5jYpJmEpGHxzAliXjO1OyJkZGqLvqflDhxfiTnuw2ZZleYhkFBFOIKGlrrKWa-QNtYqmUcBwyxZxB68aF98NnNaHtkqBxJJ1lnHgx1nkm5I2757qX2Upq4rm-kCu1sDZs0qMM_--KwHz7tunL_2UEaWplrgmAAhNuaQnHrwwNm7-wdmaRGIIzyI1zyhG2C1wdd7yun5SiOcIs7Gt0Af_f-5nsH2YDI6yo6G48PHcDNExOa4OruwWV8szBNEXHX-tHFzAqdXPbN-A5_IQAg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFL0aHZp4QXwMKAwwCB6jxrGdjweECltZGa0itKG9ZY7tsApIypoK9U_wg_h1XNdJoBPibX2KbCuNcq99z7VPzgV4kYeJtHHfM5oXmKDgTM8TJT0pC8UwInEqbaI4mYaHJ_z9qTjdgl_ttzCWVtmuieuFWlfK7pEPGAZ2DCYsjAZFQ4tI90ev5989W0HKnrS25TScixyZ1Q9M3xavxvto65dBMDo4fnvoNRUGPMVjv_akUXmSaITgvpICf0oVQuQ5VTIUCWWxr2OtGWda01D5uY6NUImUItGKa80Z3vcabEcYFeMebL85mKYfuzgQM-a0ECj1IhHRRtcI8cPAIaVYBBvR8PoXS_6--BfWvUzZ_CsGjm7BzQa8kqHzttuwZco7sDNpjufvws-hWtaGOEVkUhVk_M18_mrrhpGh1l5VkmMnYkDwMuDeOXnnGPMkdaXDiSw1tq2UpeyTT5jHOxnxFcFbpE4CdkHs3jGxCTQJSMPoWRDEv2Zmd0fIxNQWic_KXTi5EnPcg15ZleYBkECFOIIGlsbKWVRIG3eVzEOfYcYs4j48b198Nne6Htk6HxJJ1lmnD7vOJN2Qtn3vUvskTV1XNtcFdrcGzJoVYZH98d8-POu6cS7bAxpZmmqJY3yE25hPctqH-87e3T8wS5FATNGHeMMTugFWJ3yzp5ydr_XCKWJufAv04f-f6yns4IzKPoynR4_gRoDgzdF29qBXXyzNYwRfdf6k8XICZ1c9sX4DQcZENA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+Effect+of+Imeglimin+Add-on+Therapy+on+24-h+Glucose+Profile+and+Glycemic+Variability+in+Patients+with+Type+2+Diabetes+Receiving+Metformin&rft.jtitle=Medical+principles+and+practice&rft.au=Shinohara%2C+Yasutake&rft.au=Jojima%2C+Teruo&rft.au=Kamiga%2C+Yusuke&rft.au=Sakurai%2C+Shintaro&rft.date=2024-12-01&rft.issn=1011-7571&rft.eissn=1423-0151&rft.spage=1&rft.epage=9&rft_id=info:doi/10.1159%2F000540852&rft.externalDBID=n%2Fa&rft.externalDocID=10_1159_000540852 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-7571&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-7571&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-7571&client=summon |